.jpg?format=webp&quality=80&width=3840)
Despite advances in therapeutics for heart failure and arrhythmias, a substantial proportion of patients with cardiomyopathy do not respond to interventions, indicating a need to identify novel modifiable myocardial pathobiology. In addition, human genetic variants associated with severe forms of cardiomyopathy and arrhythmias have highlighted the crucial role of alternative splicing in myocardial health and disease, given that it determines which mature RNA transcripts drive the mechanical, structural, signaling, and metabolic properties of the heart. This Review discusses how technical advances in multi-omics and long-read single-cell sequencing technologies have facilitated the analysis of cardiac isoform expression. The resulting insights into the regulation of alternative splicing, including the identification of cardiac splice regulators as therapeutic targets and the development of a translational pipeline to evaluate splice modulators in human-engineered heart tissue, animal models, and clinical trials, provide a basis for improved diagnosis and therapy. Finally, it considers how the medical and scientific communities can benefit from facilitated acquisition and interpretation of splicing data to improve clinical decision-making and patient care.
Like
Save
Share